Summit Hotel Properties, Inc. (INN-PE)
| Previous Close | 20.89 |
| Open | 20.92 |
| Bid | 16.20 x 800 |
| Ask | 0.00 x 1100 |
| Day's Range | 21.00 - 21.05 |
| 52 Week Range | 17.03 - 22.48 |
| Volume | |
| Avg. Volume | 10,138 |
| Market Cap | 1.011B |
| Beta (5Y Monthly) | 1.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.58 |
| Earnings Date | May 02, 2024 |
| Forward Dividend & Yield | 1.56 (7.42%) |
| Ex-Dividend Date | Feb 14, 2024 |
| 1y Target Est | N/A |
PR NewswireSUMMIT HOTEL PROPERTIES REPORTS FIRST QUARTER 2024 RESULTS
Summit Hotel Properties, Inc. (NYSE: INN) (the "Company"), today announced results for the three months ended March 31, 2024.
CNW GroupInnocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), is pleased to announce that is has reached a key milestone: the Company submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for Innocan's Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain.
- CNW Group
Innocan Pharma Reports Full Year 2023 Results with Revenues up Nearly 6X to $13.7M
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies is pleased to announce its audited financial consolidated results for the year ended December 31, 2023.
